



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

NOV 16 2001

RECEIVED

In re application of: LI et al.

Application Serial No.: 09/348,815

Art Unit: 1635

Filed: July 8, 1999

Examiner: Zara, J.

For: Connective Tissue Growth Factor-2

Attorney Docket No.: PF126PID1

RESPONSE UNDER 37 C.F.R. § 1.111 TO PAPER NO. 15

#16/K.T.
11/21

Commissioner for Patents
Washington, D.C. 20231

RESPONSE
w/attach.

Sir:

In response to the Official Action mailed August 14, 2001 (Paper No. 15), Applicants hereby request that the Examiner's rejections be removed in light of the remarks enclosed herein. Applicants submit concurrently herewith: (a) a Fee Transmittal Sheet; (c) Exhibits A-D; (d) Version With Markings Showing Changes Made; (e) a Terminal Disclaimer under 37 C.F.R. § 1.321(b); and (f) an Associate Power of Attorney.

Remarks

Claims 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 35, 36, 39, 40, 43, 44, 47, 48, 59, 60, 61, 62, 63, 64, 65, 66, 67, 72, 73, 74, 77, 78, 81, 82, 85, and 86 are pending. Applicants respectfully request reconsideration of the rejections and objections in view of the following remarks.

Maintained Rejections

A. 35 U.S.C. §112, second paragraph

The rejection with respect to claims 23, 25, 27, 29, 33, 36, 40, 44, 48, 61, 65, 67, 74, 78, 82, and 86 are maintained as allegedly being of improper dependent form. It is asserted that the dependent claims "do not further limit the sequences, but expand them very broadly." See page 3 of Paper No. 15.